🇺🇸 FDA
Patent

US 8822196

Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer

granted A61PA61P35/00

Quick answer

US patent 8822196 (Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P35/00